Aclarion CEO to Present Nociscan Technology at Leading MedTech Conference

Aclarion, Inc., a commercial-stage healthcare technology company, announced that CEO Brent Ness will attend LSI USA 2026, a premier conference for MedTech innovators, investors, and industry leaders. During the event, Ness will meet with investors and potential partners to discuss progress on Nociscan, the company's proprietary MR spectroscopy platform that uses artificial intelligence and biomarkers to help physicians distinguish between painful and non-painful discs in chronic low back pain patients. This technology addresses a significant healthcare challenge, as chronic low back pain affects millions worldwide and often leads to costly, invasive procedures when pain sources remain unclear.

The conference, scheduled for March 16-20, 2026 in Dana Point, California, focuses on accelerating MedTech and HealthTech innovation through in-person meetings. Aclarion's participation highlights the growing importance of diagnostic technologies that can noninvasively pinpoint pain sources. Nociscan operates as a SaaS platform that receives magnetic resonance spectroscopy data from MRI machines, then uses proprietary algorithms to analyze chemical biomarkers associated with disc pain. This approach represents a shift toward more precise, evidence-based diagnostics that could reduce unnecessary surgeries and improve patient outcomes.

For more information about Aclarion's technology and updates, visit https://www.aclarion.com. The company's newsroom at https://tinyurl.com/aconnewsroom provides additional resources about their developments in healthcare technology. Nociscan's potential to transform low back pain diagnosis comes at a critical time, as healthcare systems seek more cost-effective solutions for chronic pain management. By providing clearer insights into pain locations, the technology aims to help physicians develop more targeted treatment strategies, potentially reducing the economic burden of chronic back pain estimated at billions annually in healthcare costs and lost productivity.

The implications of Aclarion's conference participation extend beyond immediate business development. Successful adoption of Nociscan could establish new standards for diagnosing spinal conditions, influencing how physicians approach one of medicine's most common and challenging problems. As the company engages with investors and partners at LSI USA 2026, it seeks to advance technology that addresses both clinical needs and healthcare system efficiencies. The conference provides a platform to demonstrate how AI-enhanced diagnostics might reshape pain management, offering hope for improved patient care through more accurate identification of pain sources before considering invasive interventions.